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Background and purpose   There has been a limited amount of 
research on survival of total hip arthroplasties (THAs) in rheuma-
toid arthritis (RA). We therefore performed a population-based, 
nationwide study to compare the survival of primary THAs in RA 
patients and in osteoarthritis (OA) patients. We also wanted to 
identify predictors of THA failure in RA patients. 
Methods      Using  the  Danish  Hip Arthroplasty  Registry,  we 
identified 1,661 primary THAs in RA patients and 64,858 in OA 
patients, all of which were inserted between 1995 and 2008. The 
follow-up period was up to 14 years for both groups.
Results   Regarding overall THA survival, the adjusted RR for 
RA patients compared to OA patients was 0.81 (95% CI: 0.65–
1.01). We found no difference in survival of cups between pri-
mary THAs in RA and OA patients. In contrast, there was better 
overall survival of stems in RA patients than in OA patients, both 
regarding revision due to aseptic loosening (adjusted RR = 0.58; 
95% CI: 0.34–0.99) and for any reason (adjusted RR = 0.63; 95% 
CI: 0.45–0.88). In RA patients, males had a higher risk of revision 
than females concerning aseptic loosening of the stem, any revi-
sion of the stem, and any revision of both components. 
Interpretation   The overall survival of primary THAs in RA 
patients is similar to THA survival in OA patients. Stem survival 
appeared to be better in RA patients, while survival of the total 
THA concept did not show any statistically significant differences 
between the two groups. In RA patients, males appear to have a 
greater risk of revision than females.

Next to osteoarthritis (OA), rheumatoid arthritis (RA) is the 
commonest reason for total hip arthroplasty (THA) (Annual 
Report,  Danish  Hip  Arthroplasty  Registry,  2009).  Several 
characteristics of RA patients, including the destructive nature 
of the disease, poor bone stock, the use of cytostatics or gluco-
corticoids for treatment, and an increased level of comorbid-
ity, may possibly contribute to a poorer THA survival in this 
group. 
Research on survival of THAs in RA patients has been lim-
ited. Some (Unger et al. 1987, Snorrason et al. 1993, Lachie-
wicz 1997, Creighton et al. 1998, Jana et al. 2001, Tang and 
Chiu 2001) but not all authors (Kirk et al. 1993, Ranawat 1998, 
Furnes et al. 2001, Eskelinen et al. 2006) have reported a poor 
prognosis of THA in RA patients, but the findings have been 
inconsistent. Several design issues may have undermined the 
existing study results, including small study samples, lack of 
long-term follow-up, incomplete follow-up, and lack of con-
trol groups (e.g. OA patients). Thus, the prognosis of THA in 
RA patients remains somewhat uncertain. 
The main aim of our study was to compare THA survival in 
RA and OA patients. In addition, we wanted to identify patient- 
and surgery-related predictors of revision in RA patients.
Patients and methods
Settings and design
In Denmark, the National Health Service provides tax-sup-
ported healthcare for all inhabitants, allowing free access to 
general practitioners and hospitals. At birth, all Danish citi-
zens  are  assigned  a  unique  10-digit  personal  identification 
number, which is used in all public registries.
Civil registration system 
This registry has kept information (updated on a daily basis) 
on death, emigration, and change of address for all Danish 
national citizens since 1968. 
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The Danish National Registry of patients 
The National Registry of Patients was established in 1977, 
and keeps data concerning both admissions and discharges 
of patients, including up to 20 discharge diagnoses, and all 
surgical procedures performed in the Danish hospitals. The 
diagnoses are classified according to the Danish version of the 
International Classification of Diseases (eighth edition up to 
1993 and tenth edition thereafter). From the registry, we col-
lected comorbidity data on all THA patients since 1977 and 
constructed the Charlson comorbidity index (Charlson et al. 
1987). This index, which was validated in 2003 (de Groot et 
al. 2003), includes 19 major disease categories including car-
diovascular, cerebrovascular, chronic pulmonary, liver, renal 
and ulcerative diseases, diabetes, and solid and hematologi-
cal tumors. Admissions from each category are weighted as 
1, 2, 3, or 6 points, and the score is the sum of these weights. 
We classified all patients according to 3 levels of comorbidity: 
low-index (individuals with a score of 0 prior to the time of 
surgery), moderate (individuals with 1 or 2 points), and high-
index (individuals with more than 2 points).
The Danish Hip Arthroplasty Registry (DHR)
We based our study on information from the DHR (Annual 
Report, Danish Hip Arthroplasty Registry, 2009), which was 
established in January 1995. The main purpose of the DHR 
is to improve the quality of both primary and revision THA 
surgery in Denmark. All orthopedics departments, including 
private hospitals, in Denmark submit detailed pre- and per-
operative data concerning THA surgeries to the DHR. These 
data have been recorded using a standardized form, which is 
filled in by the orthopedic surgeon immediately after surgery. 
The  completeness  and  validity  of  the  registry  has  already 
been evaluated (Pedersen et al. 2004) and afterwards the form 
became part of the daily routine in the registry settings. 
Since then, the completeness of the DHR has been com-
pared with the Danish National Registry of patients (which is 
assumed to be the gold standard for registration of all proce-
dures in Denmark) every 3 months. Afterwards, the orthope-
dic departments receive a list with all the patients, who have 
not been registered in the DHR, and are thereafter responsible 
for registering those patients. The result of this routine process 
has been reflected in the annual completeness of the DHR of 
more than 90% for the last 10 years (Annual report, Danish 
Hip Arthroplasty Registry, 2009).  Validation of several impor-
tant variables included in the DHR with corrections based on 
the medical records at department level is further performed 
at least once a year.
Our study population consisted of 1,661 primary THAs in 
RA patients and 64.858 primary THAs in patients with OA. 
Altogether, 266 RA patients (16%) and 10,636 OA patients 
(16%) had bilateral THA, more than 90% of which were two-
stage procedures. It has been shown previously that inclusion 
of dependent observations such as bilateral procedures on the 
same patients does not influence revision risk, even though the 
proportion of individuals undergoing bilateral surgery can be 
almost 20% (Robertsson and Ranstam 2003).
Outcome
Time to revision of the THA was taken as the endpoint. Revi-
sion was defined as removal or exchange of either of the com-
ponents or parts. Both aseptic loosening and any cause of revi-
sion were considered endpoints, and patients were followed 
until death, emigration, revision, or December 31, 2008. 
Statistics 
The Cox regression model was used to calculate both unad-
justed and adjusted hazard ratios for revision with 95% con-
fidence interval (CI) for RA compared with OA patients. The 
hazard ratio was used as a measure of relative risk (RR). We 
adjusted for age (0–59 years (reference), 60–69 years, 70–79 
years, and 80+ years), sex (female (reference)), comorbidity 
(Charlson score 0 (reference), 1–2, and 3+), duration of sur-
gery (continuous variable), and type of fixation (uncemented 
(reference), and cemented prostheses). We compared distri-
butions using chi-squared test. 2-sided p-values < 0.05 were 
considered to be statistically significant. To describe time to 
revision and absolute risk of revision, we constructed Kaplan-
Meier  plots  to  illustrate  cumulative  incidence  of  revision. 
The assumption of the Cox proportional hazards model was 
assessed graphically using log-log plots and found suitable. 
Finally, we examined the association with time to revision 
for a broad range of patient- and surgery-related factors in RA 
patients in order to identify possible predictors of revision.
The statistical analyses were performed using SAS software 
version 9.2. The study was approved by the Danish Data Pro-
tection Agency (j. no. 2009-41-3644). 
Table 1. Characteristics of THAs, patients with rheumatoid arthritis 
(RA), and patients with osteoarthritis (OA)
  RA patients  OA patients   p-value
  n  %  n  % 
Gender  Female  1203  72  36,498  56  –
  Male  458  28  28,360  44  < 0.001
Age  0–59 years  595  36  11,115  17  –
  60–69 years  544  33  21,306  33  –
  70–79 years  435  26  23,418  36  –
  > 80 years  87  5  9,019  14  < 0.001
Comorbidity 
  Low (0)  218  13  44,163  68  –
  Moderate (1–2)  1,256  76  17,010  26  –
  High (3+)  187  11  3,685  6  < 0.001
Cup  Cemented  783  47  28,077  43  – 
  Uncemented  878  53  36,781  57  0.002
Stem  Cemented  1,215  73  44,360  68  –
  Uncemented  446  27  20,498  32  < 0.001
Total  -  1,661  100  64,858  100 62  Acta Orthopaedica 2010; 81 (1): 60–65
Results
Patient characteristics (Table 1)
Most RA patients were females younger than 60 years of age 
and had a higher comorbidity score before surgery than OA 
patients, while the distribution of cemented and uncemented 
prosthetic components appeared to be similar in the RA and 
OA groups. Median age at the time of primary surgery was 64 
and 70 years in RA and OA patients, respectively. The median 
length of follow-up was 5.9 (25 to 75 percentile: 3.1–9.1) 
years for the RA group and 4.7 (25 to 75 percentile: 2.2–7.8) 
years for the OA group.
Risk of revision for total hip arthroplasty (including 
cup and stem) (Table 2)
The risk of revision of the entire cup/stem concept appeared 
to be lower in RA patients than in OA patients (adjusted RR 
of revision for any reason = 0.81; CI: 0.65–1.01); however, the 
difference did not reach statistical significance. We found sim-
ilar revision risks in RA and OA patients according to three 
time periods; thus, adjusted RR was 0.92 (CI: 0.69–1.22) for 
RA vs. OA patients operated in the period from 1995 through 
1998, adjusted RR was 0.72 (CI: 0.47–1.10) for RA vs. OA 
patients operated in the period between 1999 and 2003, and 
adjusted RR was 0.57 (CI: 0.29–1.11) for RA vs. OA patients 
operated in the period among 2004 and 2008. 
Risk of cup revision (Table 2)
The cumulative risk of revision of the cup due to aseptic loos-
ening was slightly higher for RA patients than for OA patients 
during the entire study period, being 1.0% (CI: 0.6–1.7) and 
0.6 (CI: 0.5–0.7) in RA and OA patients at 5 years follow-up, 
and reaching 5.7% (CI: 3.7–8.8) in RA patients and 4.6% (CI: 
4.0–5.1) in OA patients after 14 years of follow-up (Figure 1). 
Although it may appear that the revision risk was higher in RA 
patients, after adjusting for possible confounders we found no 
statistically significant difference in the risk of revision due to 
aseptic loosening of the cup in RA patients compared to OA 
patients (adjusted RR = 1.14; CI: 0.77–1.68). 
We did not find any statistically significant difference in the 
risk of revision for any reason (adjusted RR = 0.94; CI: 0.74–
1.20) between cups in RA patients compared to OA patients. 
After  5  years,  the  cumulative  risk  of  revision  for  RA  and 
OA patients was 2.5% (CI: 1.8–3.5) and 2.7% (CI: 2.6–2.8), 
respectively, and after 14 years the risk had increased to 11% 
(CI: 8.0–14) for the RA group and 8.6% (CI: 7.9–9.3) for the 
OA group (Figure 2). 
Risk of stem revision (Table 2)
The cumulative risk of stem revision due to aseptic loosening 
was 0.2% (CI: 0–0.7) in RA patients and 0.8% (CI: 0.7–0.9) 
in OA patients at 5 years, and after 14 years the correspond-
Table 2. Risk of revision in THA patients with rheumatoid arthritis (RA) compared to that in osteoarthritis (OA) patients. The 
p-values are connected to the adjusted RR
  Cause of revision  RA  OA  Crude RR (95% CI)  Adjusted RRa (95% CI)  p-value
  n  %  n  % 
  
Cup  Aseptic loosening  30  1.8  658  1.0  1.37 (0.95–1.98)  1.14 (0.77–1.68)  0.5
  Any cause  74  4.5  2,024  3.1  1.21 (0.96–1.53)  0.94 (0.74–1.20)  0.6
Stem  Aseptic loosening  15  0.9  752  1.2  0.61 (0.37–1.02)  0.54 (0.32–0.92)  0.02
  Any cause  48  2.9  2,082  3.2  0.77 (0.58–1.02)  0.62 (0.46–0.83)  < 0.01
Cup and stem  Any cause  89  5.4  2,979  4.6  1.00 (0.81–1.23)  0.81 (0.65–1.01)  0.07
aRelative risk of revision with 95% CI, mutually adjusted for age, gender, comorbidity, duration of surgery, and type of fixation.
Figure 1. The cumulative risk of revision of cups in RA patients and OA 
patients for aseptic loosening.
Figure 2. The cumulative risk of revision of cups in RA patients and OA 
patients for any reason.Acta Orthopaedica 2010; 81 (1): 60–65  63
ing figures were 3.2% (CI: 1.8–5.9) and 4.3% (CI: 3.8–4.8). 
Nevertheless, at the 5-year follow-up the cumulative risk of 
revision of the stem for any reason was 1.2% (CI: 0.7–1.9) for 
RA patients and 2.8% (CI: 2.7–2.9) for OA patients, reaching 
7.6% (CI: 5.4–11) for RA patients and 8.1% (CI: 7.5–8.8) for 
OA patients (Figures 3 and 4). After adjusting for possible con-
founding factors, we found statistically significantly lower risk 
of revision in stems in RA patient than in OA patients regarding 
both aseptic loosening (adjusted RR = 0.54; CI: 0.32–0.92) and 
revision for any reason (adjusted RR = 0.62; CI: 0.46–0.83).
RA subgroup
We found an increased risk of stem revision in males than in 
females concerning both aseptic loosening (adjusted RR = 8; 
CI: 2.5–25) and revision for any reason (adjusted RR = 2.3; CI: 
1.3–4.1). Furthermore, we found an increased risk of revision 
in males than in females regarding the total stem/cup concept 
and any cause of revision (adjusted RR = 1.7; CI: 1.1–2.7). 
Otherwise, we found no difference in the risk of revision due 
to aseptic loosening or any revision according to age, Charlson 
comorbidity index, duration of surgery, or fixation technique. 
Discussion
In this large nationwide population-based follow-up study, we 
found that the risk of revision following THA in RA patients 
was lower or similar to that in OA patients. Stems had a better 
survival in RA patients than in OA patients.
Strengths and limitations of our study
The main strengths of our study were its population-based 
prospective design with almost complete follow-up, and the 
large sample size. In addition, a previous study (Pedersen et 
al. 2004) reported a high validity of data in the Danish Hip 
Arthroplasty Registry, with 94% completeness of procedures 
registered and a positive predictive value of between 84% and 
100% for hip diagnoses for primary total hip replacement. In 
addition, our study was based on data collected independently 
of its objective. Completeness of registration of revisions in 
the DHR is approximately 90%. The lack of registration of 
revisions in the DHR (approximately 10%) is most likely non-
differential, i.e. independent of hip diagnosis for THA (Ped-
ersen et al. 2004). Furthermore, we adjusted for a wide range 
of possible confounders in the statistical analyses, including 
age, sex, comorbidity history, duration of surgery, and fixa-
tion technique. Previous studies did not include comorbidity 
data in the analyses as a confounder, although this is a well-
established prognostic factor for implant survival (Johnsen et 
al. 2006).
The study also has some limitations, however. First of all, 
the absolute number of revisions was moderate to low, which 
is reflected in the statistical precision of the risk estimates. 
Even though the follow-up ranged from 0 to 14 years, the rela-
tive short-term median follow-up of 5.9 and 4.7 years for RA 
and OA patients, respectively, precluded us from making con-
clusions on long-term results for THAs in RA patients.   
Although we adjusted for some confounders, we were not 
able to adjust for other possible confounders such as tobacco 
use, alcohol use, social status, and use of drugs, which might 
affect the prognosis of the THA if they were related to pri-
mary hip diagnosis. Finally, the DHR does not collect data on 
patient-related information regarding quality of life, especially 
concerning pain and level of physical activity before and after 
the surgery, which may have had an effect on implant survival 
as well.   
RA vs. OA
The cumulative risk of revision of the cups in RA patients 
found in our study is in accordance with the results from the 
Finnish register-based study (Eskelinen et al. 2006). However, 
comparison of the results is challenging because the Finnish 
study population is younger and the implant concepts used 
in RA patients are not quite the same as those used in Den-
mark. 2 other clinical studies (Ahnfelt et al. 1990; Furnes et 
al. 2001) have reported an increased risk of revision of cups 
in RA patients, attributing the poor results partly to poor bone 
Figure 3. The cumulative risk of revision of stems in RA patients and 
OA patients for aseptic loosening.
Figure 4. The cumulative risk of revision of stems in RA patients and 
OA patients for any reason.    64  Acta Orthopaedica 2010; 81 (1): 60–65
stock (Snorrason et al. 1993). 2 radiological studies have also 
confirmed these poor results with cups in RA patients (Carls-
son et al. 1986; Kobayashi et al. 1994), but these studies were 
only based on Charnley prostheses.
Several authors have reported good results concerning the 
survival of stems in RA patients (Jana et al. 2001, Keisu et 
al. 2001, Effenberger et al. 2002, Eskelinen et al. 2006), but 
most of these studies did not include a control group. We do 
not know for certain what causes RA stems to last longer than 
OA stems, but perhaps it can be explained by a lower level of 
physical activity in RA patients.  
Furnes  et  al.  (2001)  found  no  difference  in  the  10-year 
survival rate of total implants between RA patients and OA 
patients,  which  is  in  accordance  with  our  results.  Similar 
results were reported in a recent paper from the DHR (Johnsen 
et al. 2006). However, since the absolute difference in cumula-
tive revision rate estimates between RA and OA patients was 
small during the median follow up time of approximately 5–6 
years, the clinical implication of our findings is unclear.
RA subanalysis
Several earlier studies on RA patients have found a lower risk 
of revision in older patients than in younger patients (Leh-
timäki et al. 1999, Furnes et al. 2001, Eskelinen et al. 2006). 
We could not confirm these previous findings. However, we 
did find a higher risk of revision in men than in women con-
cerning both the stem and the THA as a whole. This difference 
between males and females was also reported by Eskelinen et 
al. (2006) and further confirmed by Lehtimäki et al. (1999), 
Furnes et al. (2001), and Johnsen et al. (2006) for THA patients 
in general, including RA patients. The mechanism underly-
ing the association between revision risk and male sex has not 
been well established. However, it appears likely that occupa-
tional lifting in men (Coggon et al. 2006), women’s concerns 
about  surgical  complications  and  surgical  implications  for 
their family and therefore less willingness to discuss the pos-
sibility of surgery with their physician (Hawker et al. 2000), 
and a higher referral rate from primary care physicians to any 
kind of specialist for male patients and thus a higher possibil-
ity of receiving surgery (Franks and Clancy 1997), may play 
role in this association.
A previous study from the DHR has shown that comorbid-
ity is an important predictor regarding the survival of primary 
THAs (Johnsen et al. 2006). Thus, a high Charlson comorbid-
ity index was associated with an increased risk of revision of 
all THAs, including RA and OA. We were unable to confirm 
these results for our RA patients, which could partly be due 
to the low number of RA patients with no comorbidity in our 
study. Even so, the issue of confounding by indication may 
blur our estimated risk, as RA patients with a moderate or high 
level of comorbidity may have a lower likelihood of being 
offered revision of a malfunctioning prosthesis compared to 
OA patients due to the anticipated higher operative risk.  
In several studies, aseptic loosening of cemented cups has 
been found to be disturbingly high (Cracchiolo et al. 1992, 
Lachiewicz 1997, Unger et al. 1997, Creighton et al. 1998, 
Ranawat 1998, van der Lugt et al. 2003). We did not find such 
poor results regarding the cemented cups, either due to aseptic 
loosening or for any cause of revision. These findings are in 
accordance with 2 other large registry studies (Furnes et al. 
2001, Eskelinen et al. 2006). Eskelinen et al. (2006) found 
promising results for cemented polyethylene cups, with a 10-
year survival of more than 90%, and based on these results 
they recommended this type of prosthesis as an alternative in 
younger patients. Furnes et al. (2001) did not find any sig-
nificantly worse results either, concerning this issue. The good 
results with cemented cups (compared to uncemented cups) 
reported lately may have partly contributed to several substan-
tial improvements in modern cementing techniques during the 
past 10–15 years. 
The good survival of cemented and uncemented stems in 
RA  patients  found  in  our  study  is  in  accordance  with  the 
results of several larger studies (Furnes et al. 2001, Jana et al. 
2001, Eskelinen et al. 2006). These authors all described good 
results  concerning  uncemented  porous-coated  stems,  while 
Cracchiolo et al. (1992) described good results with several 
different uncemented prostheses. 
In conclusion, the overall survival of primary THAs in RA 
patients is comparable if not better than the survival found in 
OA patients. We found a significantly lower risk of stem revi-
sion in RA patients than in OA patients, and furthermore we 
found that male sex was a risk factor for stem revision in RA 
patients.  
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